February 1, 2023. – Toronto, ON: LifeLabs is pleased to share the launch of SignateraTM, a highly sensitive, personalized molecular residual disease assay (MRD) test developed by Natera for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
The first of its kind, this innovative ...
Discontinuation of Rare Disease Testing at LifeLabs Genetics
Starting May 2, 2022, LifeLabs Genetics will no longer offer genetic tests related to Rare Disease diagnosis. However, we continue to expand our genetic test offerings in other areas, such as reproductive health, wellness, oncology and risk assessment and testing, ...
IMPORTANT UPDATE FOR PATIENTS AND CLINICS IN ONTARIO ONLY
On December 17, 2021, BORN announced NIPT for twin pregnancies, regardless of maternal age, gestational age or other factors, is now funded by the Ministry of Health. The new guidelines improve access to prenatal screening and are applicable to LifeLabs’ Panorama™ ...
New York Times recently published an article focusing on non-invasive prenatal testing and microdeletion syndromes. The article mentioned our certified lab partner, Natera.
To provide the full picture, Natera has provided some additional context here.